Format

Send to

Choose Destination
J Neuropathol Exp Neurol. 2008 Jul;67(7):720-7. doi: 10.1097/NEN.0b013e31817dd02d.

Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma.

Author information

1
Department of Neuropathology, University Hospital of Cologne, Kerpener Strasse 62, Cologne, Germany.

Abstract

Primary lymphomas of the CNS (PCNSLs) show molecular features of the late germinal center exit B-cell phenotype and are impaired in their terminal differentiation as indicated by a lack of immunoglobulin class switching. Because the positive regulatory domain I protein with ZNF domain (PRDM1/BLIMP1) is a master regulator of terminal B-cell differentiation into plasma cells, we investigated a series of 21 PCNSLs for the presence of mutations in the PRDM1 gene and alterations in the expression pattern of the PRDM1 protein. Direct sequencing of all coding exons of the PRDM1 gene identified deleterious mutations associated with abrogation of PRDM1 protein expression in 4 of 21 (19%) PCNSLs. Thus, similar to systemic diffuse large B-cell lymphomas, PRDM1 may be a tumor suppressor in some PCNSL and contribute to lymphomagenesis by impairing terminal differentiation.

PMID:
18596541
DOI:
10.1097/NEN.0b013e31817dd02d
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center